文献速递白血病

聚乙二醇门冬酰胺酶清除率升高可预测急性淋巴细胞白血病患者中的失活

Increase in peg-asparaginase clearance as a predictor for inactivation in patients with acute lymphoblastic leukemia.
PubMed 文献 · Leukemia · 2024-01-29

研究基于ALLTogether试点方案,在北欧和波罗的海国家1-45岁急性淋巴细胞白血病患者中强制监测门冬酰胺酶活性,分析253例患者的1631份实时样本,发现18.2%患者出现失活,其中93%失活患者此前有清除率升高,而无超敏反应患者中86%清除率保持稳定。

要点

  • 253例患者中18.2%出现门冬酰胺酶失活,表现为轻度过敏28.3%、重度过敏50.0%、沉默失活21.7%。
  • 药代动力学模型显示93%失活患者此前有清除率升高,无超敏反应患者中86%清除率稳定。
  • 清除率升高可预测失活,为剂量增加或换用其他门冬酰胺酶制剂提供依据。

核心结论

  • 聚乙二醇门冬酰胺酶清除率升高与后续失活相关,可预测失活并指导剂量调整或换药。

研究设计与样本

  • 研究纳入按ALLTogether试点方案治疗的北欧和波罗的海国家1-45岁急性淋巴细胞白血病患者,分析253例患者的1631份实时门冬酰胺酶活性样本,并构建药代动力学模型。

主要发现

  • 253例患者中18.2%出现失活,失活表现为轻度过敏28.3%、重度过敏50.0%、沉默失活21.7%。
  • 药代动力学转运室模型显示,93%的失活患者此前有清除率升高,而无超敏反应患者中86%在整个门冬酰胺酶治疗期间清除率保持稳定。

临床怎么用

  • 作者认为这些发现可预测失活,并提供剂量增加或换用其他门冬酰胺酶制剂的选择以优化急性淋巴细胞白血病治疗策略。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Asparaginase is an essential component of acute lymphoblastic leukemia (ALL) therapy, yet its associated toxicities often lead to treatment discontinuation, increasing the risk of relapse. Hypersensitivity reactions include clinical allergies, silent inactivation, or allergy-like responses. We hypothesized that even moderate increases in asparaginase clearance are related to later inactivation. We therefore explored mandatory monitoring of asparaginase enzyme activity (AEA) in patients with ALL aged 1-45 years treated according to the ALLTogether pilot protocol in the Nordic and Baltic countries to relate mean AEA to inactivation, to build a pharmacokinetic model to better characterize the pharmacokinetics of peg-asparaginase and assess whether an increased clearance relates to subsequent inactivation. The study analyzed 1631 real-time AEA samples from 253 patients, identifying inactivation in 18.2% of the patients. This inactivation presented as mild allergy (28.3%), severe allergy (50.0%), or silent inactivation (21.7%). A pharmacokinetic transit compartment model was used to describe AEA-time profiles, revealing that 93% of patients with inactivation exhibited prior increased clearance, whereas 86% of patients without hypersensitivity maintained stable clearance throughout asparaginase treatment. These findings enable prediction of inactivation and options for either dose increments or a shift to alternative asparaginase formulations to optimize ALL treatment strategies.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Dam M, Centanni M, Friberg LE, et al. Increase in peg-asparaginase clearance as a predictor for inactivation in patients with acute lymphoblastic leukemia. Leukemia. 2024. PMID: 38287133. doi:10.1038/s41375-024-02153-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。